House Panel Probes Wyeth Off-Label Allegations

Law360, New York (June 14, 2010, 11:44 AM EDT) -- The House Committee on Oversight and Government Reform has opened an investigation into claims that Wyeth Pharmaceuticals Inc. targeted blacks in an illegal off-label marketing scheme for kidney transplant drug Rapamune.

Oversight Committee chairman Edolphus Towns, D-N.Y., sent a letter Friday to Pfizer Inc. CEO and chairman Jeffrey Kindler notifying him that the committee will be investigating whether Wyeth — acquired by Pfizer in October — “aggressively encouraged the use of Rapamune to prevent organ rejection following heart, lung, liver, pancreas and islet cell transplants, without...
To view the full article, register now.